Colorectal cancer metastasis marker as well as detection kit and application thereof

By detecting the expression levels of IFI44, CXCL8, and MBL2 biomarkers, a quantitative PCR kit was used to address the time lag in the diagnosis of colorectal cancer metastasis, enabling early and accurate diagnosis of T3 or T4 stages and liver and lung metastases.

CN121320532APending Publication Date: 2026-01-13NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
0 Cites 0 Cited by

Patent Information

Application Number
CN202511395928.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-28
Publication Date
2026-01-13

AI Technical Summary

Technical Problem

Colorectal cancer is diagnosed late, making metastasis diagnosis difficult, especially in distant metastases outside the lymphatic system. Current technology makes it difficult to perform convenient and targeted metastasis diagnosis.

Method used

Three biomarkers, IFI44, CXCL8, and MBL2, were provided as biomarkers for colorectal cancer metastasis. Their expression levels were detected by quantitative PCR kits, and combined with ROC analysis, to achieve the diagnosis of T3 or T4 stage colorectal cancer and liver and lung metastases.

Benefits of technology

It enables early and accurate diagnosis of colorectal cancer metastases, especially efficient identification of liver and lung metastases, improving the convenience and specificity of diagnosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a colorectal cancer metastasis marker, a corresponding detection kit and application. The marker is one or more of IFI44, CXCL8 and MBL2. Database data and actual clinical data show that the colorectal cancer metastasis marker has good sensitivity and specificity in diagnosis of colorectal cancer metastasis, especially liver metastasis and lung metastasis.
Need to check novelty before this filing date? Find Prior Art